Patience needed at Merck & Co as IMPROVE-IT takes its time and triple CV combo is halted
This article was originally published in Scrip
Executive Summary
Delays seem to be the order of the day for Merck & Co's cardiovascular franchise, with its latest form 10-Q filing revealing that the company has halted its development programme for MK-0524B and that the results of the long-awaited IMPROVE-IT study of Vytorin will not now come until 2014.